Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression

Impact · against what's priced in

DFTX shares are likely to react positively to the convergence of open-label outcomes (60-70%), which provides a potential counter-narrative to the disappointing Phase III remission rates. While the primary efficacy results and regulatory path are largely expected, the retreatment data suggests a higher peak commercial ceiling than a single-dose model would imply.

DFTX+0.40

No priced-in read yet